Peptide research advances through bioregulators and new therapeutic platforms

Research into peptide biochemistry is advancing through two primary avenues: the study of bioregulator peptides and the development of more stable therapeutic platforms.

Bioregulator peptides, which consist of short amino acid sequences, are being studied for their ability to act as signaling intermediaries. Due to their low molecular weight, these peptides can undergo nuclear translocation to interact directly with DNA promoter regions and histone proteins. This interaction allows them to modulate chromatin accessibility, influence epigenetic regulation, and potentially affect telomerase activity during cellular aging.

In the field of drug development, scientists are working to overcome the rapid degradation of naturally occurring peptides in the human body. Sethera Therapeutics is utilizing an enzyme-based platform combined with synthetic biology and machine learning to transform peptides into structured molecules. This approach aims to increase stability and precision, targeting diseases such as cancer, metabolic disorders, inflammatory diseases, and infectious diseases that have been difficult to treat with traditional drugs.